Amgen stock heads into ACR week with dazodalibep update

Amgen is heading into a closely watched week of clinical presentations as the American College of Rheumatology Convergence takes place from November 8 through November 11, 2026. The most important appointment for investors is a late-breaking presentation on Wednesday, November 11, covering Phase 3 OASIZ-301 results for dazodalibep in adults with Sjogren's disease and moderate-to-severe systemic disease activity.

In an Amgen investor-relations release dated October 27, the company said the trial met its primary endpoint. At Week 48, disease activity fell by a least-squares mean of 5.6 points with dazodalibep dosed every four weeks and by 5.2 points with dosing every 12 weeks, compared with a 3.8-point reduction for placebo.

The placebo-adjusted improvements were 1.8 points for the four-week regimen and 1.4 points for the 12-week regimen. Amgen said both results were statistically significant, with adjusted p-values below 0.001 and 0.010, respectively. The treatment effect appeared as early as Week 4 and continued through the end of the 48-week study.

Pipeline Evidence Moves Into Focus

Dazodalibep also improved patient-reported dryness in the four-week dosing group. The ESSPRI dryness score declined by 2.50 points from baseline, compared with 1.33 points for placebo, while the DASPRI dryness score fell by 1.98 points versus 1.05 points for placebo. Amgen reported similar rates of treatment-emergent adverse events, serious adverse events and discontinuations across the treatment groups.

The company is positioning dazodalibep as a potential first-in-class CD40L antagonist. The investigational medicine is designed to disrupt interactions among T cells, glandular epithelial cells, B cells and other antigen-presenting cells. Amgen said there are currently no FDA-approved medicines for Sjogren's disease, leaving regulatory and clinical execution as key hurdles before any commercial opportunity can be assessed.

The November 11 presentation will provide a fuller examination of the OASIZ-301 findings. Investors are also waiting for OASIZ-303, a separate Phase 3 study in patients with high symptom burden and lower systemic disease activity. Amgen expects that trial to complete in the fourth quarter of 2026, while OASIZ-304 is evaluating long-term safety and tolerability in eligible participants from the two studies.

Amgen's broader ACR program includes long-term UPLIZNA data in IgG4-related disease and real-world evidence for KRYSTEXXA and TAVNEOS. The breadth of the program gives investors more than one pipeline catalyst, although the data remain preliminary and investigational and do not establish regulatory approval or future commercial success.

The real-time quote of Amgen stock was 414.85 euros on Lang & Schwarz at 13:01 CET on Monday, November 9, 0.24 percent above the Xetra close of Friday, November 6.

Broader U.S. equity sentiment remains a relevant backdrop for large-cap biotechnology shares; investors can follow the S&P 500 market environment separately.

More news and analyses on Amgen stock.